Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IBIO 200

Next Previous
Drug Profile

IBIO 200

Alternative Names: Coronavirus Vaccine - iBio/Beijing CC Pharming; IBIO-200; SARS-CoV-2 virus like particle vaccine-iBio

Latest Information Update: 28 Mar 2024

Print Profile Download Citation

At a glance

  • Originator Beijing CC-Pharming; iBio Inc
  • Developer Beijing CC-Pharming; iBio Inc; Texas A&M University
  • Class COVID-19 vaccines; Synthetic vaccines; Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical COVID 2019 infections

Most Recent Events

  • 28 Mar 2024 No recent reports of development identified for research development in COVID-2019-infections(Prevention) in China (Injection)
  • 09 Apr 2020 iBio signs a Memorandum of Understanding with the Infectious Disease Research Institute for IBIO 200
  • 26 Mar 2020 Preclinical trials in COVID-2019 infections (Prevention) in USA (unspecified route)

Development Overview

Introduction

IBIO 200 is a virus-like particle (VLP) based vaccine being developed by iBio and Beijing CC Pharming using iBio's FastPharming System™, for the prevention of COVID-2019 infections. The vaccine is designed to maximise uptake by antigen presenting cells in order to increase the overall immune response. A SARS-CoV-2 derived antigen is fused to a self-assembling protein partner to generate the VLP. The antigen is displayed in a repetitive structure and geometry, and the particle is decorated with oligomannose molecules to resemble the structure of a naturally occurring virus.FastPharming System™ combines vertical farming, automated hydroponics, and glycan engineering technologies wherein plants are used as bioreactors for development of vaccines and biologics. Preclinical development is underway in the US. Early research is underway in China.

As at March 2024, no recent reports of development had been identified for research development in COVID-2019-infections (Prevention) in China (Injection).

Company Agreements

In February 2020, iBio and Beijing CC Pharming entered into a collaboration to develop and test a new coronavirus vaccine to be manufactured using iBio’s FastPharming System™. Financial terms of the deal are undisclosed. [1] [2]

In April 2020,iBio signed a Memorandum of Understanding (MOU) with the Infectious Disease Research Institute (IDRI) to support iBio’s SARS-CoV-2 Virus-Like Particle (VLP) vaccine development. The MOU calls for iBio and IDRI to establish a separate, additional agreement within the next 60 days if iBio opts to include one of IDRI’s adjuvants in the COVID-19 vaccine development programme (IBIO 200). The MoU integrates IDRI into iBio’s collaboration with the Texas A&M University System to create a strong partnership that brings deep experience and advanced technologies and capabilities to the task of moving IBIO 200 into the clinic. [3]

In June 2016, Texas A&M University System entered into a development agreement with iBio for collaborative program in plant-produced pharmaceuticals. The collaboration will use the research and development resources of TAMUS with the commercial therapeutics and vaccine development and manufacturing capabilities of iBio. [4]

Key Development Milestones

In March 2020, iBio initiated preclinical studies of IBIO 200 at the Texas A&M University System (“TAMUS”) laboratories as part of the Master Joint Development Agreement established between iBio and TAMUS [5] .

As of February 2020, plant based coronavirus vaccine is in early research for the treatment of COVID-2019 infections [1] .

Patent Information

In March 2020, iBio filed four provisional patent applications number US9 012 199 with the U.S. Patent and Trademark Office (US PTO), for Virus Like Particle (VLP) platform technology and lichenase carrier immunostimulatory (“LickM”) adjuvant technology. The applications also cover vaccine manufacturing method using FastPharming system™ [6] .

Drug Properties & Chemical Synopsis

  • Formulation Injection
  • Class COVID-19 vaccines, Synthetic vaccines, Viral vaccines, Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07B-X (Other viral vaccines)

  • EPhMRA code

    J7A9 (Other specified single component)

Trial Landscape

Indication Phase 0 Phase I Phase II Phase III Phase IV
COVID 2019 infections - 1 - - -

Development Status

Summary Table

Download Data (CSV)
Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - Prevention Preclinical USA unspecified / Injection iBio Inc, Texas A&M University 26 Mar 2020
COVID 2019 infections - Prevention No development reported (Research) China unspecified / Injection Beijing CC-Pharming, iBio Inc 28 Mar 2024

Commercial Information

Involved Organisations

Organisation Involvement Countries
Beijing CC-Pharming Originator China
iBio Inc Originator USA
iBio Inc Owner USA
Beijing CC-Pharming Owner China
Texas A&M University Collaborator USA
Infectious Disease Research Institute Collaborator USA

Development History

Event Date Update Type Comment
28 Mar 2024 Phase Change - No development reported No recent reports of development identified for research development in COVID-2019-infections(Prevention) in China (Injection) Updated 28 Mar 2024
09 Apr 2020 Licensing Status iBio signs a Memorandum of Understanding with the Infectious Disease Research Institute for IBIO 200 [3] Updated 15 Apr 2020
26 Mar 2020 Phase Change - Preclinical Preclinical trials in COVID-2019 infections (Prevention) in USA (unspecified route) [5] Updated 01 Apr 2020
26 Mar 2020 Trial Update iBio plans clinical development for COVID-2019 infections [5] Updated 01 Apr 2020
11 Mar 2020 Patent Information iBio files for patent protection with the US PTO for Virus Like Particle (VLP) platform technology and lichenase carrier immunostimulatory (LickM) adjuvant technology for development of COVID-2019 vaccines in USA [6] Updated 14 Aug 2020
11 Feb 2020 Phase Change Early research in COVID-2019-infections (Prevention) in USA (unspecified route) Updated 11 Feb 2020
06 Feb 2020 Phase Change Early research in COVID-2019-infections (Prevention) in China (unspecified route) [1] Updated 11 Feb 2020
03 Feb 2020 Licensing Status iBio and Beijing CC Pharming agree to co-develop coronavirus vaccine for COVID-2019 infections [1] Updated 14 Aug 2020
13 Jun 2016 Licensing Status iBio and Texas A&M University agree co-develop vaccines [4] Updated 01 Apr 2020

References

  1. iBio and CC-Pharming Initiate Joint Development of Coronavirus Vaccine.

    Media Release

  3. iBio Expands COVID-19 Vaccine Collaboration to Include the Infectious Disease Research Institute.

    Media Release

  4. Texas A&M University System and iBio Execute Joint Development Agreement for Plant-Produced Pharmaceuticals.

    Media Release

  5. iBio Announces Advancement of COVID-19 Vaccine Program.

    Media Release

  6. iBio Announces Second COVID-19 Vaccine Program.

    Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG
Legal
Back to top